0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Otto: a 4.04 GBq (109 mCi) 68Ge/ 68Ga generator, first of its kind - extended quality control and performance evaluation in the clinical production of [ 68Ga]Ga-PSMA-11

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Here we report on the comprehensive quality control of a 4.04 GBq (109 mCi) generator supplied by itG (Munich, Germany), and used for routine production of [ 68Ga]Ga-PSMA-11 for clinical imaging. The performance of the 4.04 GBq itG 68Ge/ 68Ga generator was studied for a year and parameters including elution yield, elution profile, radioactive and stable contaminants were collected. The production yields of a series of 175 [ 68Ga]Ga-PSMA-11 clinical batches are also reported herein.

          Results

          This first-of-its-kind GMP grade 68Ge/ 68Ga generator from itG with a nominal activity of 4.04 GBq (109 mCi) showed a stable  68Ga elution profile with elution efficiency averaging 58.3 ± 3.7%. 68Ge contaminant in the eluent slightly increased over time but remained 100x lower than those reported for comparable 1.85 GBq (50 mCi) itG generators. Metal impurities were found in concentrations lower than 100 ng/ml (ppb) throughout the study. [ 68Ga]Ga-PSMA-11 was obtained in 89 ± 4% radiochemical yields and > 99% radiochemical and chemical purities.

          Conclusion

          4.04 GBq (109 mCi) itG 68Ge/ 68Ga generator is suitable for routinely produced 68Ga tracers used in the clinic. Up to 30% higher amount of final drug product was obtained as compared to the 1.85 GBq (50 mCi) itG generator, and as a result larger number of studies could be performed, while reducing the synthetic burden.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients

          Purpose The prostate-specific membrane antigen (PSMA) targeted positron-emitting-tomography (PET) tracer 68Ga-PSMA-11 shows great promise in the detection of prostate cancer. However, 68Ga has several shortcomings as a radiolabel including short half-life and non-ideal energies, and this has motivated consideration of 18F-labelled analogs. 18F-PSMA-1007 was selected among several 18F-PSMA-ligand candidate compounds because it demonstrated high labelling yields, outstanding tumor uptake and fast, non-urinary background clearance. Here, we describe the properties of 18F-PSMA-1007 in human volunteers and patients. Methods Radiation dosimetry of 18F-PSMA-1007 was determined in three healthy volunteers who underwent whole-body PET-scans and concomitant blood and urine sampling. Following this, ten patients with high-risk prostate cancer underwent 18F-PSMA-1007 PET/CT (1 h and 3 h p.i.) and normal organ biodistribution and tumor uptakes were examined. Eight patients underwent prostatectomy with extended pelvic lymphadenectomy. Uptake in intra-prostatic lesions and lymph node metastases were correlated with final histopathology, including PSMA immunostaining. Results With an effective dose of approximately 4.4–5.5 mSv per 200–250 MBq examination, 18F-PSMA-1007 behaves similar to other PSMA-PET agents as well as to other 18F-labelled PET-tracers. In comparison to other PSMA-targeting PET-tracers, 18F-PSMA-1007 has reduced urinary clearance enabling excellent assessment of the prostate. Similar to 18F-DCFPyL and with slightly slower clearance kinetics than PSMA-11, favorable tumor-to-background ratios are observed 2–3 h after injection. In eight patients, diagnostic findings were successfully validated by histopathology. 18F-PSMA-1007 PET/CT detected 18 of 19 lymph node metastases in the pelvis, including nodes as small as 1 mm in diameter. Conclusion 18F-PSMA-1007 performs at least comparably to 68Ga-PSMA-11, but its longer half-life combined with its superior energy characteristics and non-urinary excretion overcomes some practical limitations of 68Ga-labelled PSMA-targeted tracers. Electronic supplementary material The online version of this article (doi:10.1007/s00259-016-3573-4) contains supplementary material, which is available to authorized users.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.

            Prostate-specific membrane antigen (PSMA) is a recognized target for imaging prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results with [(18)F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Impact of 68 Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis

                Bookmark

                Author and article information

                Contributors
                niw2014@med.cornell.edu
                job2060@med.cornell.edu
                Journal
                EJNMMI Radiopharm Chem
                EJNMMI Radiopharm Chem
                EJNMMI Radiopharmacy and Chemistry
                Springer International Publishing (Cham )
                2365-421X
                3 February 2020
                3 February 2020
                December 2020
                : 5
                : 5
                Affiliations
                [1 ]ISNI 000000041936877X, GRID grid.5386.8, Citigroup Biomedical Imaging Center, , Weill Cornell Medicine, ; 516 E 72nd St, New York, NY 10021 USA
                [2 ]ISNI 0000 0001 2152 0791, GRID grid.240283.f, Radiochemistry Laboratory, Albert Einstein College of Medicine, Department of Radiology, , Montefiore Medical Center, ; Bronx, NY USA
                [3 ]ISNI 000000041936877X, GRID grid.5386.8, Division of Radiopharmaceutical Sciences, Department of Radiology, , Weill Cornell Medicine, Belfer Research Building, ; Room 1600, 413 E 69th St, New York, NY 10021 USA
                [4 ]ISNI 000000041936877X, GRID grid.5386.8, Molecular Imaging Innovations Institute (MI3), Department of Radiology, , Weill Cornell Medicine, ; New York, NY USA
                [5 ]ISNI 000000041936877X, GRID grid.5386.8, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, ; New York, NY USA
                Author information
                http://orcid.org/0000-0002-1616-3416
                Article
                87
                10.1186/s41181-019-0087-y
                6997319
                32016646
                b05d96d2-04b3-4796-b846-dc5a0d7ecbe1
                © The Author(s) 2020

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 30 September 2019
                : 20 December 2019
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2020

                68ga/68ga generator,68ga,gallium-68,[68ga]ga-psma-11
                68ga/68ga generator, 68ga, gallium-68, [68ga]ga-psma-11

                Comments

                Comment on this article